Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer.
Bellmunt J, Guillem V, Paz-Ares L, González-Larriba JL, Carles J, Albanell J, Tabernero JM, Cortés-Funes H, Baselga J. Bellmunt J, et al. Among authors: guillem v. Eur J Cancer. 2000 Jul;36 Suppl 2:17-25. doi: 10.1016/s0959-8049(00)00081-2. Eur J Cancer. 2000. PMID: 10908844 Review.
Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
Bellmunt J, Albanell J, Paz-Ares L, Climent MA, González-Larriba JL, Carles J, de la Cruz JJ, Guillem V, Díaz-Rubio E, Cortés-Funes H, Baselga J; Spanish Oncology Genitourinary Group. Bellmunt J, et al. Among authors: guillem v. Cancer. 2002 Aug 15;95(4):751-7. doi: 10.1002/cncr.10762. Cancer. 2002. PMID: 12209718 Free article. Clinical Trial.
Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.
Bellmunt J, Guillem V, Paz-Ares L, González-Larriba JL, Carles J, Batiste-Alentorn E, Sáenz A, López-Brea M, Font A, Nogué M, Bastús R, Climent MA, de la Cruz JJ, Albanell J, Banús JM, Gallardo E, Diaz-Rubio E, Cortés-Funes H, Baselga J. Bellmunt J, et al. Among authors: guillem v. J Clin Oncol. 2000 Sep 15;18(18):3247-55. doi: 10.1200/JCO.2000.18.18.3247. J Clin Oncol. 2000. PMID: 10986057 Clinical Trial.
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.
Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, de la Cruz JJ, Taron M, Rosell R, Baselga J; Spanish Oncology Genitourinary Group. Bellmunt J, et al. Among authors: guillem v. Ann Oncol. 2007 Mar;18(3):522-8. doi: 10.1093/annonc/mdl435. Epub 2007 Jan 17. Ann Oncol. 2007. PMID: 17229776 Free article.
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer.
Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, Antón A, Laurent C, Mayordomo JI, Estaun N, Losa I, Guillem V, Garcia-Conde J, Tisaire JL, Baselga J. Tabernero J, et al. Among authors: guillem v. Ann Oncol. 2004 Sep;15(9):1358-65. doi: 10.1093/annonc/mdh349. Ann Oncol. 2004. PMID: 15319242 Free article. Clinical Trial.
Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain.
González-Larriba JL, Serrano S, Alvarez-Mon M, Camacho F, Casado MA, Díaz-Pérez JL, Díaz-Rubio E, Fosbrook L, Guillem V, López-López JJ, Moreno-Nogueira JA, Toribio J. González-Larriba JL, et al. Among authors: guillem v. Eur J Cancer. 2000 Dec;36(18):2344-52. doi: 10.1016/s0959-8049(00)00304-x. Eur J Cancer. 2000. PMID: 11094308 Clinical Trial.
A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.
Bellmunt J, Maroto-Rey P, Trigo JM, Carles J, Guillem V, López-Martín JA, Antón-Torres A, Urruticoechea L. Bellmunt J, et al. Among authors: guillem v. Clin Transl Oncol. 2010 Jul;12(7):503-8. doi: 10.1007/s12094-010-0544-2. Clin Transl Oncol. 2010. PMID: 20615828 Clinical Trial.
Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.
García-Carbonero R, Mayordomo JI, Tornamira MV, López-Brea M, Rueda A, Guillem V, Arcediano A, Yubero A, Ribera F, Gómez C, Trés A, Pérez-Gracia JL, Lumbreras C, Hornedo J, Cortés-Funes H, Paz-Ares L. García-Carbonero R, et al. Among authors: guillem v. J Natl Cancer Inst. 2001 Jan 3;93(1):31-8. doi: 10.1093/jnci/93.1.31. J Natl Cancer Inst. 2001. PMID: 11136839 Free article. Clinical Trial.
71 results